Published 2 days ago • loading... • Updated 19 hours ago

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

On Tuesday, December 16, 2025, Nektar Therapeutics hosted an investor call and live webcast to review topline results from the 36-week induction period in the Phase 2b REZOLVE‑AA trial.
Rezpegaldesleukin is described as a novel, first‑in‑class regulatory T‑cell stimulator that aims to proliferate Tregs across autoimmune indications, including alopecia areata.
Nektar announced from San Francisco that it is headquartered there and provided investor contact Vivian Wu and media contact Jonathan Pappas for inquiries.
Slides and the press release were posted on Nektar events page, and a webcast replay will be available for at least 30 days.
Beyond REZPEG, Nektar Therapeutics is evaluating NKTR‑0165 and NKTR‑0166 as preclinical programs, and NKTR‑255 in clinical trials to boost immune response, the company said.

Insights by Ground AI

20 Articles

Hanford Sentinel

+19 Reposted by 19 other sources

Center

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week…

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year